company background image
1099 logo

Sinopharm Group SEHK:1099 Stock Report

Last Price

HK$21.50

Market Cap

HK$67.1b

7D

-4.7%

1Y

-19.6%

Updated

22 May, 2024

Data

Company Financials +

Sinopharm Group Co. Ltd.

SEHK:1099 Stock Report

Market Cap: HK$67.1b

1099 Stock Overview

Engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China.

About the company

1099 fundamental analysis
Snowflake Score
Valuation6/6
Future Growth1/6
Past Performance2/6
Financial Health4/6
Dividends5/6

Rewards

Trading at 46.3% below our estimate of its fair value
Earnings are forecast to grow 6.64% per year
Earnings have grown 9% per year over the past 5 years
Pays a reliable dividend of 4.11%
Trading at good value compared to peers and industry
Analysts in good agreement that stock price will rise by 23.8%

Risk Analysis

No risks detected for 1099 from our risk checks.

Sinopharm Group Co. Ltd. Competitors

Guangzhou Baiyunshan Pharmaceutical Holdings

SEHK:874

HK$53.3b

Shanghai Pioneer Holding

SEHK:1345

HK$2.4b

Tycoon Group Holdings

SEHK:3390

HK$3.2b

IVD Medical Holding

SEHK:1931

HK$1.9b

Price History & Performance

Summary of all time highs, changes and price drops for Sinopharm Group
Historical stock prices
Current Share PriceHK$21.50
52 Week HighHK$27.30
52 Week LowHK$17.44
Beta0.83
1 Month Change2.38%
3 Month Change-4.66%
1 Year Change-19.63%
3 Year Change-19.48%
5 Year Change-26.99%
Change since IPO16.09%

Recent News & Updates

Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 46% Discount?

May 13
Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 46% Discount?

Is Sinopharm Group (HKG:1099) A Risky Investment?

Apr 22
Is Sinopharm Group (HKG:1099) A Risky Investment?

Recent updates

Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 46% Discount?

May 13
Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 46% Discount?

Is Sinopharm Group (HKG:1099) A Risky Investment?

Apr 22
Is Sinopharm Group (HKG:1099) A Risky Investment?

Investors Could Be Concerned With Sinopharm Group's (HKG:1099) Returns On Capital

Mar 21
Investors Could Be Concerned With Sinopharm Group's (HKG:1099) Returns On Capital

Should You Think About Buying Sinopharm Group Co. Ltd. (HKG:1099) Now?

Mar 06
Should You Think About Buying Sinopharm Group Co. Ltd. (HKG:1099) Now?

Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 29% Discount?

Jan 31
Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 29% Discount?

Is Sinopharm Group (HKG:1099) A Risky Investment?

Jan 15
Is Sinopharm Group (HKG:1099) A Risky Investment?

There Is A Reason Sinopharm Group Co. Ltd.'s (HKG:1099) Price Is Undemanding

Dec 31
There Is A Reason Sinopharm Group Co. Ltd.'s (HKG:1099) Price Is Undemanding

Returns On Capital Signal Tricky Times Ahead For Sinopharm Group (HKG:1099)

Nov 29
Returns On Capital Signal Tricky Times Ahead For Sinopharm Group (HKG:1099)

If EPS Growth Is Important To You, Sinopharm Group (HKG:1099) Presents An Opportunity

Nov 14
If EPS Growth Is Important To You, Sinopharm Group (HKG:1099) Presents An Opportunity

Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 28% Discount?

Nov 01
Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 28% Discount?

Should You Investigate Sinopharm Group Co. Ltd. (HKG:1099) At HK$22.45?

Sep 20
Should You Investigate Sinopharm Group Co. Ltd. (HKG:1099) At HK$22.45?

Is Sinopharm Group (HKG:1099) Using Too Much Debt?

Sep 05
Is Sinopharm Group (HKG:1099) Using Too Much Debt?

Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled

Aug 18
Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled

Are Sinopharm Group Co. Ltd. (HKG:1099) Investors Paying Above The Intrinsic Value?

Aug 02
Are Sinopharm Group Co. Ltd. (HKG:1099) Investors Paying Above The Intrinsic Value?

Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly

Jun 01
Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly

Sinopharm Group's (HKG:1099) Returns Have Hit A Wall

Apr 26
Sinopharm Group's (HKG:1099) Returns Have Hit A Wall

These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well

Feb 27
These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well

Sinopharm Group (HKG:1099) Has Some Way To Go To Become A Multi-Bagger

Jan 19
Sinopharm Group (HKG:1099) Has Some Way To Go To Become A Multi-Bagger

Is Sinopharm Group (HKG:1099) A Risky Investment?

Nov 18
Is Sinopharm Group (HKG:1099) A Risky Investment?

Returns At Sinopharm Group (HKG:1099) Appear To Be Weighed Down

Oct 03
Returns At Sinopharm Group (HKG:1099) Appear To Be Weighed Down

Is Sinopharm Group (HKG:1099) Using Too Much Debt?

Jul 31
Is Sinopharm Group (HKG:1099) Using Too Much Debt?

Estimating The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)

Jul 10
Estimating The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)

Slowing Rates Of Return At Sinopharm Group (HKG:1099) Leave Little Room For Excitement

Jun 05
Slowing Rates Of Return At Sinopharm Group (HKG:1099) Leave Little Room For Excitement

We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt

Apr 11
We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt

A Look At The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)

Mar 21
A Look At The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)

Sinopharm Group (HKG:1099) Hasn't Managed To Accelerate Its Returns

Mar 03
Sinopharm Group (HKG:1099) Hasn't Managed To Accelerate Its Returns

Is Sinopharm Group (HKG:1099) Using Too Much Debt?

Jan 09
Is Sinopharm Group (HKG:1099) Using Too Much Debt?

Sinopharm Group Co., Ltd.'s (HKG:1099) Intrinsic Value Is Potentially 28% Above Its Share Price

Dec 19
Sinopharm Group Co., Ltd.'s (HKG:1099) Intrinsic Value Is Potentially 28% Above Its Share Price

Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled

Dec 01
Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled

These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well

Sep 23
These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well

A Look At The Fair Value Of Sinopharm Group Co., Ltd. (HKG:1099)

Sep 10
A Look At The Fair Value Of Sinopharm Group Co., Ltd. (HKG:1099)

Return Trends At Sinopharm Group (HKG:1099) Aren't Appealing

Aug 28
Return Trends At Sinopharm Group (HKG:1099) Aren't Appealing

Sinopharm Group (HKG:1099) Is Increasing Its Dividend To HK$0.84

Jun 13
Sinopharm Group (HKG:1099) Is Increasing Its Dividend To HK$0.84

Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly

Jun 06
Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly

Is Sinopharm Group Co., Ltd. (HKG:1099) Expensive For A Reason? A Look At Its Intrinsic Value

May 24
Is Sinopharm Group Co., Ltd. (HKG:1099) Expensive For A Reason? A Look At Its Intrinsic Value

Sinopharm Group's (HKG:1099) Returns Have Hit A Wall

May 11
Sinopharm Group's (HKG:1099) Returns Have Hit A Wall

Have Insiders Been Selling Sinopharm Group Co., Ltd. (HKG:1099) Shares?

Mar 20
Have Insiders Been Selling Sinopharm Group Co., Ltd. (HKG:1099) Shares?

We Think Sinopharm Group (HKG:1099) Is Taking Some Risk With Its Debt

Mar 05
We Think Sinopharm Group (HKG:1099) Is Taking Some Risk With Its Debt

You Have To Love Sinopharm Group Co., Ltd.'s (HKG:1099) Dividend

Feb 18
You Have To Love Sinopharm Group Co., Ltd.'s (HKG:1099) Dividend

Should You Be Impressed By Sinopharm Group's (HKG:1099) Returns on Capital?

Feb 03
Should You Be Impressed By Sinopharm Group's (HKG:1099) Returns on Capital?

Should You Use Sinopharm Group's (HKG:1099) Statutory Earnings To Analyse It?

Jan 19
Should You Use Sinopharm Group's (HKG:1099) Statutory Earnings To Analyse It?

At HK$19.00, Is It Time To Put Sinopharm Group Co., Ltd. (HKG:1099) On Your Watch List?

Jan 06
At HK$19.00, Is It Time To Put Sinopharm Group Co., Ltd. (HKG:1099) On Your Watch List?

What Type Of Shareholders Make Up Sinopharm Group Co., Ltd.'s (HKG:1099) Share Registry?

Dec 25
What Type Of Shareholders Make Up Sinopharm Group Co., Ltd.'s (HKG:1099) Share Registry?

Read This Before Buying Sinopharm Group Co., Ltd. (HKG:1099) Shares

Dec 15
Read This Before Buying Sinopharm Group Co., Ltd. (HKG:1099) Shares

We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt

Dec 04
We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt

Sinopharm Group's (HKG:1099) Stock Price Has Reduced 43% In The Past Five Years

Nov 25
Sinopharm Group's (HKG:1099) Stock Price Has Reduced 43% In The Past Five Years

Shareholder Returns

1099HK HealthcareHK Market
7D-4.7%-2.0%1.4%
1Y-19.6%-20.6%3.2%

Return vs Industry: 1099 exceeded the Hong Kong Healthcare industry which returned -22.2% over the past year.

Return vs Market: 1099 underperformed the Hong Kong Market which returned 1.6% over the past year.

Price Volatility

Is 1099's price volatile compared to industry and market?
1099 volatility
1099 Average Weekly Movement4.7%
Healthcare Industry Average Movement7.1%
Market Average Movement7.5%
10% most volatile stocks in HK Market15.9%
10% least volatile stocks in HK Market3.7%

Stable Share Price: 1099 has not had significant price volatility in the past 3 months.

Volatility Over Time: 1099's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2003115,959Yong Liuwww.sinopharmgroup.com.cn

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail pharmacy stores, and clinics.

Sinopharm Group Co. Ltd. Fundamentals Summary

How do Sinopharm Group's earnings and revenue compare to its market cap?
1099 fundamental statistics
Market capHK$67.09b
Earnings (TTM)HK$9.58b
Revenue (TTM)HK$645.12b

7.0x

P/E Ratio

0.1x

P/S Ratio

Is 1099 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1099 income statement (TTM)
RevenueCN¥598.32b
Cost of RevenueCN¥550.17b
Gross ProfitCN¥48.15b
Other ExpensesCN¥39.26b
EarningsCN¥8.88b

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)2.85
Gross Margin8.05%
Net Profit Margin1.48%
Debt/Equity Ratio62.9%

How did 1099 perform over the long term?

See historical performance and comparison

Dividends

4.1%

Current Dividend Yield

31%

Payout Ratio

Does 1099 pay a reliable dividends?

See 1099 dividend history and benchmarks
When do you need to buy 1099 by to receive an upcoming dividend?
Sinopharm Group dividend dates
Ex Dividend DateJun 17 2024
Dividend Pay DateAug 13 2024
Days until Ex dividend25 days
Days until Dividend pay date82 days

Does 1099 pay a reliable dividends?

See 1099 dividend history and benchmarks
Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.